Persistent Suppression of the Pituitary-Gonadal System in Female Rats by Three-Month Depot Injectable Microspheres of Leuprorelin Acetate
article
OA: closed
CC0
Abstract
The serum drug levels and pharmacological effects of leuprorelin acetate (leuprolide acetate) in female rats after subcutaneous (sc) injection of 3-month release injectable and biodegradable microspheres were investigated. After sc injection, the microspheres provided sustained serum drug levels for > 3 months, probably because of continuous release of the drug. As was found for the 1-month depot preparation, a transient initial high peak in serum leuprorelin levels resulting from an initial burst of drug release could not be avoided. Sustained suppression of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol for > 16 weeks was attained by a single injection of the microspheres. An injection of the microspheres suppressed the growth of the ovaries and uterus in a dose-dependent manner; a drug dose of 0.036 mg (corresponding to approximately 1 microgram/kg/day) was insufficient for suppression of uterine growth, and a drug dose of 3.6 mg (corresponding to approximately 100 micrograms/kg/day) provided the strongest growth suppression in both organs. Serum LH, FSH, and estradiol responses in a challenge test indicated that definite pharmacological effects were sustained for at least 16 weeks, as was demonstrated previously in male rats and dogs. Thus, this depot formulation may provide sustained therapeutic effects for 3 or 4 months in humans.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study 1990
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis 1992
- One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. 1988
References (22)
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis via openalex
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study via openalex
- One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. via openalex
- W159019070 via openalex
- W167413684 via openalex
- W223380701 via openalex
- W237605412 via openalex
- W1558772894 via openalex
- W1974933001 via openalex
- W1983602876 via openalex
- W1997662342 via openalex
- W2019022309 via openalex
- W2029825520 via openalex
- W2043018121 via openalex
- W2047548978 via openalex
- W2083669220 via openalex
- W2086101502 via openalex
- W2095536362 via openalex
- W2297593361 via openalex
- W2397913582 via openalex
- W116555158 via openalex
- W95249665 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0
· commercial use OK